Healthcare Executive Faints During Oval Office Announcement
Gordon Findlay, Healthcare Executive of Novo Nordisk, fainted on Thursday at the Oval Office during a weight loss drug announcement.
Event Interrupted
The GLP-1 event was paused as President Donald Trump and Dr. Mehmet Oz turned their attention to Findlay. The press was asked to leave the room.
“During the Most Favored Nations Oval Office Announcement, a representative with one of the companies fainted,” said White House Press Secretary Karoline Leavitt. “The White House Medical Unit quickly jumped into action, and the gentleman is okay. The Press Conference will resume shortly.”
Announcement Details
President Trump announced a deal with Eli Lilly and Novo Nordisk to offer some obesity drugs to Americans at approximately $150 for a one-month supply.
Incident During Eli Lilly CEO's Speech
Findlay fainted while Eli Lilly CEO David Ricks was speaking, prompting the press to be evacuated and Dr. Kennedy to seek medical help, according to Deputy Press Secretary Kush Desai.
The press conference resumed by 1:29 p.m.
Summary
This unexpected incident briefly interrupted a major health policy announcement but was quickly managed without serious health concerns.
Author’s summary: During a White House event unveiling affordable obesity drugs, Novo Nordisk's executive fainted, causing a temporary pause but no lasting disruption.